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Abstract
High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treat-
ment. Recent attempts to identify molecular targets for specific therapies have shown that
Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. How-
ever, few inhibitors for the potential treatment for NRAS mutant neuroblastoma have been
investigated so far. In this in-vitro study, we show that MEK inhibitors AZD6244, MEK162
and PD0325901 block cell growth in NRASmutant neuroblastoma cell lines but not in
NRAS wild-type cell lines. Several studies show that mutant NRAS leads to PI3K pathway
activation and combined inhibitors of PI3K/mTOR effectively block cell growth. However,
we observed the combination of MEK inhibitors with PI3K or AKT inhibitors did not show
synergestic effects on cell growth. Thus, we tested single mTOR inhibitors Everolimus and
AZD8055. Interestingly, Everolimus and AZD8055 alone were sufficient to block cell growth
in NRAS mutant cell lines but not in wild-type cell lines. We found that Everolimus alone
induced apoptosis in NRAS mutant neuroblastoma. Furthermore, the combination of mTOR
and MEK inhibitors resulted in synergistic growth inhibition. Taken together, our results
show that NRASmutant neuroblastoma can be targeted by clinically available Everolimus
alone or in combination with MEK inhibitors which could impact future clinical studies.
Introduction
Neuroblastoma is a developmental tumor of early childhood arising from the neural crest [1,
2]. Neuroblastomas show biologic heterogeneity spanning a wide range of clinical behaviors
from spontaneous regressions to lethal outcome. High-risk patients account for 50% of all new
neuroblastoma diagnosis and cause about 13% of all pediatric cancer mortality despite multi-
modal treatment [1]. To improve therapy by identifying novel targets, four studies performing
genome sequencing of 36–240 patients detected point mutations and structural alterations in
ARID1A/B, PTPN11, MYCN, ALK and NRAS [3–5]. Anaplastic lymphoma kinase (ALK) has
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been studied as a putative drug target. ALK is mutated in about 8% of primary neuroblastomas
and can be blocked by ALK inhibitors such as Crizotinib which reduce cell growth and induce
apoptosis in cell lines [6, 7]. Two NRAS and one HRAS mutation were described in two of the
genomic landscape studies of neuroblastoma [4, 5]. NRAS mutations are found in various can-
cers including melanoma (20–25%), lung cancer (1%), acute myeloid leukemia (10%) and cuta-
neous T-cell lymphoma patients (4%) [8–10]. Mutations of NRAS are found at typical hotspots
including codon 12, 13 and 61 which results in G12C/S, G13R/V and Q61R/L mutations.
These mutations block GTPase activity and lock the RAS isoforms in continuous activation in
which they signal to downstream effectors such as MEK and ERK [11]. Direct targeting of
mutant NRAS by farnesylation inhibitors have failed but blocking downstreamMEK kinase by
MEK kinase inhibitors was successful in a preclinical setting. Different MEK inhibitors specifi-
cally block cell growth and induce apoptosis in melanoma, neuroblastoma, lung cancer and T-
cell lymphoma cell lines [9, 12, 13]. More important, targeting NRAS by MEK inhibitors
MEK162 (Binimetinib) was shown to be efficient in a phase II clinical trial with 30 melanoma
patients [14]. Partial responses were observed in 20% of treated patients while 43% were pre-
senting with stable disease [14]. Several studies could show that mutant NRAS activates the
PI3K/mechanistic target of rapamycin (mTOR)-signaling cascade in melanoma and lung can-
cer [13, 15]. Further, combined inhibition of MEK and PI3K pathways was synergistic [13, 15].
However, these studies used combined PI3K/mTOR inhibitors currently in preclinical and
early clinical evaluation [13, 15]. It is not known whether inhibition of both targets is required
or whether inhibition of PI3K or mTOR alone would suffice to impact tumor growth and
survival.
Here, we investigated the druggability of NRAS in neuroblastoma. We show that NRAS can
be targeted by MEK inhibitors AZD6244 (Selumetinib) and MEK162 whereas wild-type cells
are refractory to this treatment. We observed that single PI3K inhibitors were ineffective in
blocking PI3K signaling and also cell growth. However, the use of single mTOR inhibitors
Everolimus and AZD8055 resulted in a significant reduction of cell growth exclusively in
NRAS mutant cell lines. More importantly, Everolimus alone was sufficient to induce apoptosis
in NRAS mutant neuroblastoma cell lines but not in wild-type cell lines. Moreover, combina-
tion of mTOR and MEK inhibitors block cell growth synergistically. These findings open new
perspectives in the treatment of high-risk and relapsed neuroblastoma.
Methods
Patient Samples
Patient samples are derived from high-risk neuroblastoma patients as described in [4] as part
of the NCI funded TARGET project (https://ocg.cancer.gov/programs/target). The Children's
Hospital of Philadelphia Institutional Review Board approved this study and was responsible
for oversight of this study. Flash-frozen tumor samples were analyzed for percent tumor con-
tent by histopathology, and samples with<75% tumor content were excluded.
Chemicals
AZD6244, MEK162, BKM120 and PD0325901 were purchased from Selleck Chemical. Everoli-
mus, AZD8055, GSK690693, MK2206 and BKM120 (as a control) were purchased fromMed-
ChemExpress. All inhibitors were solubilized in dimethyl sulfoxide (DMSO) at stock
concentrations of 1mM.
Targeting Mutant NRAS by Everolimus
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Cell Culture
CHP-212 and SK-N-AS were purchased from ATCC. NGP and CHP-134 were purchased
from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Germany).
SH-SY5Y was provided by Prof. A. Aguzzi, Institute of Neuropathology, Zurich. CHP-212 cells
were cultured in DMEM and F12 medium (1:1) supplemented with 10% fetal calf serum (FCS)
and 1mM L-glutamine. SK-N-AS cells were cultured in DMEM supplemented with 0.1mM
non-essential amino acids and 1mM L-glutamine. NGP cells were cultured in high-glucose
DMEM (4.5 g/L glucose) supplemented with 10% FCS. SH-SY5Y cells were cultured in DMEM
supplemented with 10% FCS. All cell lines were purchased within less than one year and regu-
larly tested for mycoplasma contamination.
siRNA Transfection and Knock-Down
CHP-212, SK-N-AS, SH-SY5Y, CHP-134 and NGP were transfected with either control or two
different siRNAs against NRAS (Dharmacon, A-003919-13-0005, A-003919-14-0005). Accell
siRNA was purchased from Dharmacon and used according to manufactor’s protocol. In brief,
siRNAs were diluted in Accell siRNA Delivery Media from Dharmacon to a final concentration
of 1μM. Knockdown efficiency was observed after 96 hours.
Western Blot Analysis
Western Blots were performed as described previously [9]. In brief, 0.5x106 cells were lysed for
30 minutes in ice-cold MPERM buffer supplemented with 25mMNaF, 1mM dithiothreitol,
and complete protease inhibitor cocktail from Roche Diagnostics. Cell debris was removed by
centrifugation and then, proteins were blotted onto a nitrocellulose membrane (GE Health-
care) followed by blocking with 5% bovine serum albumin in phosphate-buffered saline/Tween
(0.05% Tween-20 in phosphate-buffered saline). The following antibodies were used: anti-
phospho-ERK (P-p44/p42 (Tyr202/204, #9101, Cell Signaling Technology), anti-ERK (p44/
p42, # 4695, Cell Signaling Technology), anti-phospho Akt (Ser473, # 4085, Cell Signaling
Technology), anti-panAKT (# 9272, Cell Signaling Technology), anti-phospho MEK (Ser298,
#9128, Cell Signaling Technology), anti-MEK (# 8727, Cell Signaling Technology), anti-phos-
pho mTOR (Ser2448, #2971, Cell Signaling Technology), anti-mTOR (# 2972, Cell Signaling
Technology), anti-phospho S6 (Ser235/236, Cell Signaling Technology), anti-S6 (#2317, Cell
Signaling Technology), anti-NRAS rabbit (# ab97488, Abcam) and anti—tubulin (Sigma-
Aldrich).
PCR and Sequencing of Cell Lines
Identification of mutations was performed as described previously [9]. Total cellular RNA was
isolated using the Qiagen RNA Purification Kit (Qiagen). 1μg of RNA was reverse transcribed
with a reverse transcription-PCR kit (Applied Biosystems); 5 μL of cDNA was used for a PCR
of 50 μL volume. The following primers were used: NRAS forward, 5’-ggggtctccaacatttttcc-3’;
NRAS reverse, 5’-cccagggcagaaaaataaca-3’. PCR was performed, and 30 μL of PCR product
was sent for sequencing to Microsynth, Switzerland. For sequencing, the same primers were
used as for PCR. Mutations were verified in Cancer Cell Line Encyclopedia or COSMIC data-
base [16].
Apoptosis Assays
Cell lines were treated with indicated concentrations of inhibitors and apoptosis was measured
after 48 hours and 72 hours. Apoptosis was assessed by AnnexinV—APC (Enzo Lifescience)
Targeting Mutant NRAS by Everolimus
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and propidium iodide (PI) (Sigma-Aldrich) by FACS. Both reagents were diluted to a final con-
centration of 1.5%. Specific cell death was calculated by the following equation: specific cell
death % = (% experimental cell death—% spontaneous cell death)/(100%—% spontaneous cell
death) x 100 [17].
Cell Growth and Viability Assays
Cell growth was measured with the Cell-Titer-Glo Reagent (Promega) according to manufac-
turer’s instructions. Cells were plated in 96-well plates at a density of 500–2500 cells per well.
The next day, drugs were added at indicated concentrations and cell growth was measured 96
hours later. Proliferation was made with a 96-well plate luminometer/plate reader (Synergy 2,
Biotek). Data shown are calculated as relative values for a given drug concentration compared
to non-treated cells. All experimental points were set up in duplicate replicates and were con-
ducted at least 3 independent times. IC50 were calculated with GraphPad Primsm. Combina-
tion index (CI) values with CalcuSyn Software (Biosoft) according to Chou [18]. CI values less
than one were considered synergistic.
Results
Characteristics of Patients with Neuroblastoma that Harbor NRAS
Mutations
Within the TARGET consortium whole genome or whole exome sequencing of newly diag-
nosed matched neuroblastoma tumor and blood-derived DNAs was performed [4, 19]. We
found 3 NRAS-mutated cases in 299 predominantly high-risk patients with whole genome or
whole exome sequencing (Table 1). One additional NRAS-mutated case was identified in addi-
tional 500 patients who are of low-, intermediate- and high-risk neuroblastoma. In total, we
identified 4 NRAS-mutant cases among 799 tested (0.5%) and, 3 out of 4 mutations occurred
in high-risk patients (Table 1). One of the tumors had a NRAS G13R while 3 harbored a NRAS
G61K mutation (Table 1). Clinical characteristics of patients with NRAS mutations are sum-
marized in Table 1.
MEK Inhibitors Block Cell Growth in NRASMutated Neuroblastoma
Cancer Cell Lines
Analysis of the NRAS gene in our panel of neuroblastoma cell lines revealed two NRAS muta-
tions at position Q61K in the CHP-212 and SK-N-AS cell line, which was also the most com-
mon mutation in the primary tumors (Tables 1 and 2).
The identified mutations were found to be heterozygous (Table 2). These mutations are
well-known to lead to oncogenic activation of NRAS [11]. To investigate the effect of MEK
inhibition, we applied three different MEK inhibitors; two are currently in clinical development
[14, 20]. We observed dose-dependent growth inhibition of the NRAS mutant neuroblastoma
cell lines CHP-212 and SK-N-AS treated with MEK inhibitors AZD6244, MEK162 and
PD0301925 (Fig 1A–1C). These results are in agreement with previously published data show-
ing that NRAS mutations sensitize towards MEK inhibitors [9, 12, 13, 15]. NRAS wild-type
neuroblastoma cell lines SH-SY5Y, CHP-134 and NGP were refractory to MEK inhibitors even
at high micromolar concentrations. The calculated IC50 values for AZD6244 for CHP-212 and
SK-N-AS were 0.8nM and 418nM respectively (S1B Fig). Of note, these are clinically achievable
plasma concentrations since maximal plasma concentrations of AZD6244 and MEK162 were
at 1.75 μM and 1.13 μM, respectively [21, 22]. In line with these observations, inhibition of
MEK blocks downstream ERK phosphorylation in NRAS mutant cell lines (Fig 1D). MEK
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phosphorylation itself is not blocked by MEK inhibitors but rather increased as shown previ-
ously [9, 23]. Finally, MEK162 suppressed clonogenic growth in NRAS mutant cell lines CHP-
212 and SK-N-AS for 10 days (Fig 1E). Taken together, these data show that NRAS Q61K
mutations in neuroblastoma result in hyperactivation of the RAS/RAF/MEK/ERK pathway
and sensitize to MEK inhibitors.
Mutant NRAS Is Indispensable for Survival of NRAS Mutant
Neuroblastoma
The effect of NRAS knock-down was studied to investigate whether NRAS mutations are
required for survival of mutant cell lines. We performed a specific NRAS knock-down with
two different siRNAs. The knock-down efficiency of the siRNAs was comparable in all cell
lines (S1C Fig). Interestingly, the NRAS Q61K neuroblastoma cell lines SK-N-AS and CHP-
212 showed a significant decrease in cell growth after siRNA mediated NRAS knock-down,
compared to cells transfected with non-targeting control siRNA (S1B Fig). We conclude that
NRAS activity is required for viability of NRAS mutant neuroblastoma. In addition, we found
that MEK inhibitor MEK162 might induce cell death in NRAS mutant cell lines CHP-212 and
to a lower extend in SK-N-AS (S2A Fig).
NRASMutant Neuroblastoma Is Insensitive to PI3K Inhibition
Recently published studies showed that mutant NRAS melanoma and neuroblastoma cells are
highly sensitive to the combination of MEK and combined PI3K/mTOR inhibitors which are
in preclinical or early clinical development [13, 15]. However, it is unclear whether inhibition
of either PI3K or mTOR alone is sufficient. Thus, we intended to examine the growth inhibi-
tory effect of single PI3K inhibitors or in combination with MEK inhibitors. However, we
found that activation of AKT measured by phosphorylation levels of AKT Ser473 did not
change remarkably upon PI3K inhibitor treatment with BKM120 (Buparlisib) (Fig 2A). Thus,
we further investigated phosphorylation levels at AKT Thr308. However, background phos-
phorylation of Thr308 was barley detected in CHP-212 and SK-N-AS cell lines (S3A Fig). To
assure that the BKM120 would be generally functional in this setting, we used the multiple
myeloma cell line L-363 as a positive control. In previous screening experiments in our lab, L-
Table 1. Characteristics of individual patients with NRAS-mutant tumors.
RAS mutation Gender INSS Stage COG risk group MYCN status OS (Days) treatment OS
Patient 1 NRAS (G13R) Female Stage 4 High Not Ampliﬁed 647 Dead
Patient 2 NRAS (Q61K) Female Stage 4 High Ampliﬁed 765 Alive
Patient 3 NRAS (Q61K) Female Stage 4 Intermediate Not Ampliﬁed 480 Dead
Patient 4 NRAS (Q61K) Female Stage 4 High Not Ampliﬁed 521 Alive
doi:10.1371/journal.pone.0147682.t001
Table 2. NRAS und ALKmutations in selected neuroblastoma cell lines. Cell lines were sequenced for
NRASmutations. Results were evaluated by Genetic Analysis Technology Consortium sequence viewer.
NRAS ALK
CHP-212 Q61K -
SK-N-AS Q61K -
SH-SY5Y - F1174L
CHP-134 - -
NGP - -
doi:10.1371/journal.pone.0147682.t002
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Fig 1. MEK inhibition blocks cell growth in NRASmutant cells. A-C) All indicated cell lines were kept under equal conditions. Cell lines were left
untreated or treated with indicated concentrations of the 3 MEK inhibitors AZD6244, MEK162 and PD0325901 for 96 hours. Then, cell growth was measured
by ATP changes by Cell Titer Glo according to the manufacturer’s instructions. IC50 were calculated with GraphPad Prims and statistical difference
calculated with t-test. *** p < 0.0001. D) All cell lines were kept under equal conditions, then treated with 500nM of the MEK inhibitors AZD6244, MEK162
and PD0325901 for 1 hour and next lysed and subjected to Western blot. Phosphorylation levels of ERK and MEK were detected by specific anti-phospho
antibodies. Loading was verified by specific antibodies to total ERK, MEK and anti—tubulin. E) Crystal violet stain of CHP-212 and SK-N-AS cells from a
clonogenic assay after 10 d treatment with DMSO (ctr), 0.001μM, 0.01 μM, 0.1μM and 1μMMEK162.
doi:10.1371/journal.pone.0147682.g001
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Fig 2. Blocking the PI3K pathway does not influence cell growth or signaling. A) CHP-212 and SK-N-AS cells were treated with 500nM of the MEK
inhibitor MEK162 or the PI3K inhibitor BKM120 for 1 hour and next lysed and subjected to Western blot. Phosphorylation levels of AKT, ERK and S6 were
detected by specific anti-phospho antibodies. Loading was verified by specific antibodies to total AKT, ERK and anti—tubulin. B) CHP-212 and SK-N-AS
cells were treated with 500nM of MEK162 or BKM120 or combinations thereof as indicated for 96h. Then, cell growth was assessed by Cell titer Glo. C)
Same as B) but the AKT1/2/3 inhibitor GSK690693 was used instead of BKM120. D) Same as C) but the AKT1/2/3 inhibitor MK2206 was used instead of
GSK690693.
doi:10.1371/journal.pone.0147682.g002
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363 was one of the very few cell lines that showed a relevant IC50 towards BKM120 (data not
shown). Indeed, BKM120 and another PI3K inhibitor GDC0032 effectively blocked AKT phos-
phorylation at Ser473 in L-363 (S3B and S3C Fig) proving that BKM120 is able to block the
PI3K pathway in certain cell lines. Regarding the NRAS mutant neuroblastoma, this might
implicate that phosphorylation of AKT is independent of upstream PI3K activity in these cell
lines and that mutant NRAS does not signal via the PI3K/AKT axis. These observations were
supported by the finding of cell growth experiments. Combination of BKM120 with MEK
inhibitor MEK162 did not enhance cell growth inhibition compared to MEK inhibitor treat-
ment alone in both cell lines (Fig 2B). To further support these data, we used the AKT1/2/3
inhibitors GSK690693 and MK2206. GSK690693 alone or in combination with MEK162 had
no effect on cell growth (Fig 2C). We obtained a comparable result for MK2206 for the CHP-
212 cell line (Fig 2D). Other reports have shown that combined inhibition by PI3K/mTOR
inhibitors block cell growth [13]. Our data suggest that the PI3K/AKT pathway is, at least in
these model systems, not relevant for survival and cell growth of NRAS mutant neuroblastoma
cells.
mTOR Inhibitor Everolimus in Single Use Reduces Cell Growth and
Leads to Apoptosis in NRASMutant Neuroblastoma Cell Lines
Targeting of the PI3K/AKT pathway seemed not to have some effect on NRAS mutant neuro-
blastoma cells. Since combined inhibitors of PI3K/mTOR showed activity in previous studies,
we hypothesized that inhibition of the down-stream mTOR complex could be sufficient. We
chose the FDA-approved mTOR inhibitor Everolimus which would be readily available for fur-
ther clinical evaluation. As a control, the mTOR kinase inhibitor AZD8055, which inhibits
both mTORC1 and mTORC2 complexes, was used [24]. Both inhibitors showed equally capa-
bility in blocking mTOR assessed by phosphorylation levels of downstream S6 kinase (Fig 3A).
Strikingly, inhibition of the mTOR pathway alone resulted in a strong blockage of cell growth
in NRAS mutant neuroblastoma cancer cell lines compared to wild-type (Fig 4B). IC50 values
for CHP-212 and SK-N-AS were both<1nM (Fig 3B). Maximal plasma concentrations for
Everolimus in patients with pediatric tumors were reported to be between 16.7nM and 97.8nM
depending on dosing applied [25]. Mean plasma concentrations over 24 hours for Everolimus
ranged between 6-14nM [25]. This indicated that IC50 values for both NRAS mutant neuro-
blastoma cell lines were at a sensitive level for plasma concentrations of Everolimus. In addi-
tion, the mTOR1/2 inhibitor AZD8055 showed a similar outcome (Fig 3C). AZD8055 blocked
cell growth also in wild-type cell lines, though to a lesser extent than in NRAS mutant cell lines
(Fig 3C). This might indicate a certain degree of dependency on mTORC2 signaling in wild-
type cell lines. Next, we evaluated whether inhibition of cell growth by Everolimus also
inducted apoptosis. Indeed, Everolimus caused significant apoptosis exclusively in NRAS
mutant cell lines but not in NRAS wild-type cell lines (Fig 3D). In summary, inhibition of
mTOR complex alone by Everolimus reduced cell growth and induced apoptosis in NRAS
mutant neuroblastoma.
Combined Inhibition of MEK and mTOR Synergistically Reduces Cell
Growth in NRASMutant Neuroblastoma Cell Lines
Encouraged by these findings, we aimed to investigate how the combination of mTOR inhibi-
tors and MEK inhibitors would affect cell growth of NRAS mutant neuroblastoma cell lines. If
used together, the combination of Everolimus and AZD6244 / MEK162 caused a stronger inhi-
bition of S6 kinase than monotherapy as detected by Western Blot (Fig 4A). The combination
of Everolimus and AZD6244 / MEK162 also resulted in a stronger blockade of cell growth in
Targeting Mutant NRAS by Everolimus
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Fig 3. Inhibition of mTOR reduces cell growth in NRASmutant cell lines. A) CHP-212 and SK-N-AS cells were treated with 5nM of the mTOR inhibitors
Everolimus or 250nM AZD8055 for 1 hour. Then, cells were lysed and analysed byWestern blot. B) All indicated cell lines were left untreated or treated with
indicated concentrations of Everolimus for 96 hours. Next, cell growth was measured by Cell Titer Glo according to the manufacturer’s instructions C) Same
as B) but the mTOR inhibitor AZD8055 was used instead. D) NRASmutant and wild-type cell lines were incubated with indicated concentrations of
Everolimus for 72 hours. Then, apoptosis was determined by Annexin V and PI staining.
doi:10.1371/journal.pone.0147682.g003
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Fig 4. Combined blockage of mTOR and MEK pathways reduces cell growth synergistically. A) CHP-212 and SK-N-AS cells were treated with
indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells were lysed and
analysed byWestern blot. Phosphorylation levels of AKT, ERK and S6 were detected by specific anti-phospho antibodies. Loading was verified by specific
antibodies to total AKT, ERK and anti—tubulin. B) CHP-212 cells were treated with indicated concentrations of AZD6244, MEK162 or Everolimus or
combinations thereof for 96h. Then, cell growth was measured by Cell Titer Glo. Combination index (CI) values with CalcuSyn Software (Biosoft). C) Same
Targeting Mutant NRAS by Everolimus
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NRAS mutant cells than monotherapy (Fig 4B and 4C). To further strengthen our results, we
investigated the effect at different timepoints. We found that synergistic activity can be
observed after 3 or 4 days whereas day 2 might to early to observe relevant toxicity (S4A–S4C
Fig). Notably, concentrations used for combined inhibition had very low nanomolar concen-
trations for both Everolimus and AZD6244 or MEK162 (Fig 4B and 4C). Importantly, the
combination of Everolimus and MEK inhibitors was found to have significant synergistical
effect according to Chou [18]. Synergy is defined if the combination index (CI) is below 1 [18].
We found the CI values to be between 0.29 and 0.43 which indicates strong synergy (Fig 4B
and 4C). Also the combination of AZD8055 and MEK was synergistic. AZD8055 blocked
downstream phosphorylation of S6 kinase alone (Fig 4A). Yet, phosphorylation of S6 kinase
and cell growth was further blocked when AZD8055 was used in combination with MEK
inhibitors (Fig 4A, 4D and 4E). To summarize, these data show that combination of mTOR
and MEK inhibitors synergistically inhibit downstream signaling and cell growth of NRAS
mutant cell lines.
Discussion
NRAS mutations are found in various malignancies including melanoma (20%), adenocarci-
noma of the lung (1%), neuroblastoma (0.83%) and cutaneous T-cell lymphoma (4%). We and
others have shown that NRAS mutations sensitize towards inhibition of MEK in cutaneous T-
cell lymphoma, lung cancer and neuroblastoma cell lines [9, 12, 13, 15]. These findings are
now further supported by demonstrating that knock-down of mutant NRAS causes growth
inhibition exclusively in NRAS mutant neuroblastoma cell lines (S1 Fig). Many studies explore
the potential use of dual inhibition of MAPK and PI3K/AKT/mTOR which results in growth
inhibition in NRAS mutant melanoma and neuroblastoma [13, 15]. However, combined inhib-
itors targeting both PI3K and mTOR were used in these studies. We found that single inhibi-
tion of PI3K or AKT alone had no effect on cell growth of NRAS mutant neuroblastoma which
is concordant with the results from Vujic et al. (Fig 2) [15]. We observed that the PI3K or AKT
inhibitors alone or in combination with MEK inhibitors did not alter cell growth (Fig 2). How-
ever, we found that BKM120 alone or in combination with MEK inhibitors does block S6 phos-
phorylation downstream independent of its activity on AKT phosphorylation (Fig 2). Further,
this activity couldn´t be correlated to effects on cell growth. We thus assume that BKM120
might have unspecific activity on PI3K/AKT or that the activity has to be correlated to other
currently unknown biomarkers than AKT and S6 phosphorylation. Recently, it was shown that
the combination of MEK inhibitor AZD6244 and AKT inhibitor MK2206 are effective in
KRAS mutated cancers [26]. The combination treatment of AKT and MEK inhibitiors was sig-
nificantly synergistic compared to mono therapy [26]. Moreover, this early trial reported an
impressive response rate of AKT and MEK combination in KRAS mutant non-small cell lung
cancer (NSCLC) patients [26]. However, we could not observe a synergism of AKT inhibitor
MK2206 and MEK inhibitors AZD6244 and MEK162 in NRAS mutant neuroblastoma cell
lines (data not shown). This might be explained by different downstream signaling of the dif-
ferent RAS family members. For instance, BRAF and NRAS mutations can be efficiently tar-
geted by MEK inhibitors alone both in cell lines and in patients, resulting in significant
response rates [27–29]. However, KRAS mutations alone are not a strong indicator for
response to MEK inhibitors demonstrated by a study that shows that roughly one half of cell
lines with KRAS mutations responded to AZD6244 whereas the other half did not [30].
as B) but AZD8055 was used instead of Everolimus. D) SK-N-AS cells were treated with indicated concentrations of AZD6244 or Everolimus or combinations
thereof for 96h. Then, cell growth was measured by Cell Titer Glo. E) Same as D) but AZD8055 was used instead of Everolimus.
doi:10.1371/journal.pone.0147682.g004
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Therefore, it has been speculated whether additional cellular pathways are involved in mediat-
ing the viability of KRAS-transformed cells which supports the concept of synthetic lethality
[31].
In our study, we demonstrate that inhibition of the mTOR pathway by Everolimus alone is
sufficient to block cell growth in NRAS mutant neuroblastoma cells compared to wild type
cells (Fig 3). More importantly, Everolimus induced apoptosis significantly in NRAS mutant
neuroblastoma CHP-212 cells (Fig 3). This is an intriguing finding since Everolimus is cur-
rently indicated and available for the treatment of renal cell cancer and pancreatic neuroendo-
crine tumors and could be of value for carefully selected patients with NRAS mutant
neuroblastomas. Since blocking mTOR alone seemed to generate a similar outcome in cell
growth as MEK inhibitors, we speculated whether combination of both drugs would be able to
further potentiate inhibition. Interestingly, combination of MEK and mTOR inhibitors is syn-
ergistic in NRAS mutant neuroblastoma cell lines which were observed for both cell lines (Fig
4). Whether combinations of MEK and mTOR or even MEK and combined AKT/mTOR
inhibitors can be used in clinical setting regarding site effects is currently investigated. Phase I
trials reported good tolerability for the combination of the MEK inhibitor pimasertib and the
PI3K/mTOR inhibitor SAR245409 in 53 patients [32]. Currently, it is unclear how mutant
NRAS signals to the mTOR complex without involving upstream PI3K and AKT. This merits
further investigation to maybe improve combined targeting of both pathways or to identify
other involved molecules that could be directly targeted.
In conclusion, we show that mutant NRAS neuroblastoma can be targeted by single MEK
and mTOR inhibitors or their combinations. Especially Everolimus as currently available drug
could be an alternative option for NRAS mutated neuroblastoma patients being refractory to
other treatments.
Supporting Information
S1 Fig. Mutations in neuroblastoma cell lines and Knock-down of mutant NRAS leads to
inhibition of cell growth. A) PCR obtained from cDNA of respective cell lines were sequenced
by Sanger sequencing for the complete NRAS coding region. B) Cell lines were incubated with
indicated concentrations of MEK162 and IC50 values were calculated with GraphPad Prism.
C) Accell siRNA against NRAS (siNRAS1 and siNRAS2) was transfected in NRAS mutant can-
cer cell lines according to manufactor´s instruction. Then, 96h later cells were lysed and lysates
subjected to Western blot. Efficiency of knock-down was measured by anti-NRAS antibodies.
Equal loading was controlled by anti-tubulin antibodies. D) Accell siRNA against NRAS (siN-
RAS1 and siNRAS2) was transfected in NRAS mutant cancer cell lines according to manufac-
tor´s instruction. 96 hours after transfection cell growth was assessed by Cell titer Glo. P values
were calculated with t-test and  defined as p<0.05.
(EPS)
S2 Fig. MEK162 induces cell death in NRAS mutant cell lines. A) NRAS mutant and NRAS
wild-type cell lines were incubated with indicated concentrations of MEK inhibitors MEK162
for 72 hours. Then, cell death was determined by Annexin V and PI staining.
(EPS)
S3 Fig. BKM120 does not affect AKT phosphorylation in neuroblastoma but in sensitive
lymphoma cell lines. A) CHP-212, SK-N-AS and BT-474 (used as planned positive control)
cells were treated with 0.5μM and 1μM of BKM120 for 3 hours. Then, cells were lysed and ana-
lysed by Western blot. B) L-363 was used a positive control to investigate whether BKM120
might work in our hands. L-363 cells were treated with 0.5μM and 1μM of BKM120 or
Targeting Mutant NRAS by Everolimus
PLOS ONE | DOI:10.1371/journal.pone.0147682 January 28, 2016 12 / 15
GDC0032 for 3 hours. Then, cells were lysed and analyzed by Western blot. C) L-363 was left
untreated or treated with indicated concentrations of BKM120 for 96 hours. Next, cell growth
was measured by Cell Titer Glo according to the manufacturer’s instructions.
(EPS)
S4 Fig. Combined blockage of mTOR and MEK pathways reduces cell growth synergisti-
cally at different time points. A) CHP-212 cells were treated with MEK162 or Everolimus or
combinations thereof as indicated for 48h. Then, cell growth was assessed by Cell titer Glo. B)
Same as C) but the readout was done after 72h. C) Same as B) but the readout was done after
96h. Combination index (CI) values with CalcuSyn Software (Biosoft).
(EPS)
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